Hyaluronic acid–polyethyleneimine conjugate for target specific intracellular delivery of siRNA

Ge, Jingping; Park, Kitae; Kim, Jiseok; Kim, Ki Su; Oh, Eun‐Suok; Kang, Hyungu; Han, Su-Eun; Oh, Yu‐Kyoung; Park, Tae Gwan; Hahn, Sei Kwang

doi:10.1002/bip.20978

Cited by 139 publications

(99 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies indicate that HA exhibits strong anticancer activity by inhibiting the metastasis and growth of cancer cells. 17,18 The combination of PTX and HA was shown to achieve additional or synergistic antimetastasis effects. 19 In addition, the outer HA shell in the nanoparticles is capable of evading nonspecific uptake by the reticuloendothelial system, thus enhancing the accumulation of the HA-based nanoparticle in the tumor.…”

Section: Introductionmentioning

confidence: 99%

Nanoparticle delivery and combination therapy of gambogic acid and all-trans retinoic acid

Yao¹,

Li²,

Sun³

et al. 2014

IJN

View full text Add to dashboard Cite

In order to enhance the in vivo codelivery efficiency of gambogic acid (GA) and all-trans retinoic acid (ATRA), our strategy was to entrap GA in the self-assembled nanoparticles based on amphiphilic hyaluronic acid (HA)-ATRA (HRA) conjugate. In this way, GA and ATRA were loaded simultaneously in a nanocarrier and codelivered into the tumor cell through HA receptor-mediated endocytosis. GA-loaded HRA nanoparticles (GA-HRA) were prepared by a dialysis method, and their physicochemical characteristics were investigated as well. GA-HRA exhibited a high drug loading capacity (31.1%), had a particle size in the range of 100–150 nm, and good biocompatibility. HRA nanoparticles were effectively internalized by MCF-7 cells and translocated into the nucleus in a time-dependent manner. The in vivo imaging analysis demonstrated that the fluorescent signals in the tumor were markedly increased with DiR-loaded nanoparticles after intravenous administration compared to free DiR solution, suggesting it has excellent tumor targeting properties. More importantly, GA-HRA exhibited excellent in vivo efficacy with dramatically reduced toxicity. In conclusion, with the assistance of HRA nanoparticles, GA and ATRA can successfully realize an effective combination chemotherapy as well as tumor-targeted delivery.

show abstract

Section: Introductionmentioning

confidence: 99%

Nanoparticle delivery and combination therapy of gambogic acid and all-trans retinoic acid

Yao¹,

Li²,

Sun³

et al. 2014

IJN

View full text Add to dashboard Cite

show abstract

“…HA has been widely used in the past as a targeted delivery material because of its carboxyl groups, which can form bonds with other molecules. Polycations such as poly-L-lysine (PLL) 10) and polyethyleneimine (PEI) 11,12) were covalently bonded via amide bond formation between the amine groups of polycations and the carboxyl groups of HA, and these materials enabled the target-specific delivery of HA to receptor positive cells in vitro 11,12) and to liver endothelial cells in vivo. 10) Further, HA nanogels, in which thiol-conjugated HA was crosslinked via disulfide linkages, was used as a target specific siRNA delivery cargo.…”

mentioning

confidence: 99%

Synthesis and Evaluation of Stearylated Hyaluronic Acid for the Active Delivery of Liposomes to Liver Endothelial Cells

Toriyabe

Hayashi

Hyodo

et al. 2011

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Hyaluronic acid (HA) is a naturally-occurring ligand that can be useful for targeting liver endothelial cells. We describe herein the development of a new HA-lipid conjugate for the efficient delivery of liposomes to liver endothelial cells. When free HA coated cationic liposomes were injected into mice, their accumulation in the liver was significantly decreased depending on the content of free HA, while accumulation in the lung was not significantly changed. When cationic liposomes modified with HA-stearylamine (HA-SA conjugate) were injected in mice, liver accumulation was increased depending on the amount of HA-SA conjugate and accumulation in the lung was drastically reduced, compared to non-modified liposomes. Confocal imaging analyses showed that HA-SA modified liposomes were accumulated to a greater extent along with blood vessels than non-modified liposomes, suggesitng that HA-SA modified liposomes are distributed in endothelial cells in the liver. Collectively, these findings indicate that an HA-SA conjugate is a useful material that can be used to modify liposomes and for delivering bioactive liposomal cargoes to liver endothelial cells.

show abstract

“…HA-PEI conjugates can form complexes with siRNA, miRNA, or pDNA by electrostatic interaction between negatively charged nucleic acids and the positively charged PEI moiety of the HA-PEI conjugate ( Figure 5B) [41][42][43][44][45][46][47]. HA-PEI conjugates formed via an amide bond between the carboxyl groups of HA and the amine groups of branched PEI showed speci ic gene silencing ef icacy by the addition of siRNA/HA-PEI polyplexes into tumor cells [42].…”

Section: Polyplexes and Lipoplexes Modifi Ed With Hyaluronic Acidmentioning

confidence: 99%

“…HA-PEI conjugates formed via an amide bond between the carboxyl groups of HA and the amine groups of branched PEI showed speci ic gene silencing ef icacy by the addition of siRNA/HA-PEI polyplexes into tumor cells [42]. Han et al also reported that HA-PEI could ef iciently deliver siRNAs and antisense oligonucleotides (ODNs) into tumor cells with low cytotoxicity [45].…”

Section: Polyplexes and Lipoplexes Modifi Ed With Hyaluronic Acidmentioning

confidence: 99%

Progress in the development of Lipoplex and Polyplex modified with Anionic Polymer for efficient Gene Delivery

Hattori¹

2017

J Genet Med Gene Ther

View full text Add to dashboard Cite

Nucleic acid-based therapy has become an increasingly important strategy for treating a variety of human diseases. In systemic therapy, a therapeutic gene must be delivered effi ciently to its target tissues without side effects. To deliver a therapeutic gene such as plasmid DNA (pDNA) or small interfering RNA (siRNA) to target tissues by systemic administration, cationic carriers such as cationic liposomes and polymers have been commonly used as a non-viral vector. However, the binary complex of therapeutic gene and cationic carrier must be stabilized in the blood circulation by avoiding agglutination with blood components, because electrostatic interactions between positively charged complexes and negatively charged erythrocytes can cause agglutination, and the agglutinates contribute to high entrapment of the therapeutic genes in the highly extended lung capillaries. One promising approach for overcoming this problem is modifi cation of the surface of cationic complexes with anionic biodegradable polymers such as hyaluronic acid, chondroitin sulfate, or polyglutamic acid. As another approach, we recently developed a sequential injection method of anionic polymer and cationic liposome/therapeutic gene complex (cationic lipoplex) for delivery of a therapeutic gene into the liver or liver metastasis. In this review, we describe recent advances in the delivery of therapeutic genes by lipid-and polymerbased carrier systems using anionic polymers.

show abstract

Hyaluronic acid–polyethyleneimine conjugate for target specific intracellular delivery of siRNA

Cited by 139 publications

References 78 publications

Nanoparticle delivery and combination therapy of gambogic acid and all-trans retinoic acid

Nanoparticle delivery and combination therapy of gambogic acid and all-trans retinoic acid

Synthesis and Evaluation of Stearylated Hyaluronic Acid for the Active Delivery of Liposomes to Liver Endothelial Cells

Progress in the development of Lipoplex and Polyplex modified with Anionic Polymer for efficient Gene Delivery

Contact Info

Product

Resources

About